Cargando…
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study
BACKGROUND: Non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) infections are frequently associated with exacerbations of chronic obstructive pulmonary disease (COPD). Results were reported with a two-dose (0–2 months) schedule of an investigational AS01(E)-adjuvanted NTHi-M...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069748/ https://www.ncbi.nlm.nih.gov/pubmed/35509077 http://dx.doi.org/10.1186/s12931-022-02019-4 |
_version_ | 1784700496545579008 |
---|---|
author | Galgani, Ilaria Annaratone, Margherita Casula, Daniela Di Maro, Gennaro Janssens, Michel Tasciotti, Annaelisa Schwarz, Tino Ferguson, Murdo Arora, Ashwani Kumar |
author_facet | Galgani, Ilaria Annaratone, Margherita Casula, Daniela Di Maro, Gennaro Janssens, Michel Tasciotti, Annaelisa Schwarz, Tino Ferguson, Murdo Arora, Ashwani Kumar |
author_sort | Galgani, Ilaria |
collection | PubMed |
description | BACKGROUND: Non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) infections are frequently associated with exacerbations of chronic obstructive pulmonary disease (COPD). Results were reported with a two-dose (0–2 months) schedule of an investigational AS01(E)-adjuvanted NTHi-Mcat vaccine containing three surface proteins from NTHi and one from Mcat. We evaluated the safety and immunogenicity of three NTHi-Mcat vaccine doses administered in two different schedules to adults with a smoking history (≥ 10 pack-years), immunologically representing the COPD population. METHODS: In this 18-month, randomised (1:1), observer-blind study with 6-month open follow-up, 200 healthy adults aged 40–80 years received NTHi-Mcat vaccine at 0–2–6 months and placebo at 12 months (0–2–6 group), or vaccine at 0–2–12 months and placebo at 6 months (0–2–12 group). Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days, respectively, post-vaccination, and potential immune-mediated diseases (pIMDs) and serious AEs (SAEs) throughout the study. Immune responses were assessed. RESULTS: No safety concerns were identified with the third vaccine dose or overall. Most solicited AEs were mild/moderate. Unsolicited AEs were reported in 16%, 16.1% and 14.4% of participants in the 0–2–6 group post-dose 1, 2 and 3, respectively, and 20%, 20.4% and 9.7%, respectively, in the 0–2–12 group. In 24 months, SAEs were reported in 12 participants in the 0–2–6 group and 9 in the 0–2–12 group (18 events in each group). There were three deaths (unknown cause, 0–2–6 group; myocardial infarction, lung cancer in 0–2–12 group). pIMDs were reported in three participants in the 0–2–6 group (non-serious inflammatory bowel disease, gout, psoriasis) and three in the 0–2–12 group (serious ulcerative colitis, two with non-serious gout). The SAEs, deaths and pIMDs were considered not causally related to vaccination. Antigen-specific antibody concentrations were higher at 12 months post-dose 1 with the 0–2–6 schedule than with the 0–2–12 schedule and at 12 months post-dose 3 were similar between schedules, remaining higher than baseline. CONCLUSIONS: No safety concerns were identified when the investigational NTHi-Mcat vaccine was administered via a 0–2–6 months or 0–2–12 months schedule to older adults with a smoking history. Persistent immune responses were observed after the third vaccine dose. Trial registration https://clinicaltrials.gov/; NCT03443427, registered February 23, 2018. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02019-4. |
format | Online Article Text |
id | pubmed-9069748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90697482022-05-05 Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study Galgani, Ilaria Annaratone, Margherita Casula, Daniela Di Maro, Gennaro Janssens, Michel Tasciotti, Annaelisa Schwarz, Tino Ferguson, Murdo Arora, Ashwani Kumar Respir Res Research BACKGROUND: Non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) infections are frequently associated with exacerbations of chronic obstructive pulmonary disease (COPD). Results were reported with a two-dose (0–2 months) schedule of an investigational AS01(E)-adjuvanted NTHi-Mcat vaccine containing three surface proteins from NTHi and one from Mcat. We evaluated the safety and immunogenicity of three NTHi-Mcat vaccine doses administered in two different schedules to adults with a smoking history (≥ 10 pack-years), immunologically representing the COPD population. METHODS: In this 18-month, randomised (1:1), observer-blind study with 6-month open follow-up, 200 healthy adults aged 40–80 years received NTHi-Mcat vaccine at 0–2–6 months and placebo at 12 months (0–2–6 group), or vaccine at 0–2–12 months and placebo at 6 months (0–2–12 group). Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days, respectively, post-vaccination, and potential immune-mediated diseases (pIMDs) and serious AEs (SAEs) throughout the study. Immune responses were assessed. RESULTS: No safety concerns were identified with the third vaccine dose or overall. Most solicited AEs were mild/moderate. Unsolicited AEs were reported in 16%, 16.1% and 14.4% of participants in the 0–2–6 group post-dose 1, 2 and 3, respectively, and 20%, 20.4% and 9.7%, respectively, in the 0–2–12 group. In 24 months, SAEs were reported in 12 participants in the 0–2–6 group and 9 in the 0–2–12 group (18 events in each group). There were three deaths (unknown cause, 0–2–6 group; myocardial infarction, lung cancer in 0–2–12 group). pIMDs were reported in three participants in the 0–2–6 group (non-serious inflammatory bowel disease, gout, psoriasis) and three in the 0–2–12 group (serious ulcerative colitis, two with non-serious gout). The SAEs, deaths and pIMDs were considered not causally related to vaccination. Antigen-specific antibody concentrations were higher at 12 months post-dose 1 with the 0–2–6 schedule than with the 0–2–12 schedule and at 12 months post-dose 3 were similar between schedules, remaining higher than baseline. CONCLUSIONS: No safety concerns were identified when the investigational NTHi-Mcat vaccine was administered via a 0–2–6 months or 0–2–12 months schedule to older adults with a smoking history. Persistent immune responses were observed after the third vaccine dose. Trial registration https://clinicaltrials.gov/; NCT03443427, registered February 23, 2018. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02019-4. BioMed Central 2022-05-04 2022 /pmc/articles/PMC9069748/ /pubmed/35509077 http://dx.doi.org/10.1186/s12931-022-02019-4 Text en © GlaxoSmithKline Biologicals S.A 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Galgani, Ilaria Annaratone, Margherita Casula, Daniela Di Maro, Gennaro Janssens, Michel Tasciotti, Annaelisa Schwarz, Tino Ferguson, Murdo Arora, Ashwani Kumar Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study |
title | Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study |
title_full | Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study |
title_fullStr | Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study |
title_full_unstemmed | Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study |
title_short | Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study |
title_sort | safety and immunogenicity of three doses of non-typeable haemophilus influenzae-moraxella catarrhalis (nthi-mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069748/ https://www.ncbi.nlm.nih.gov/pubmed/35509077 http://dx.doi.org/10.1186/s12931-022-02019-4 |
work_keys_str_mv | AT galganiilaria safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy AT annaratonemargherita safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy AT casuladaniela safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy AT dimarogennaro safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy AT janssensmichel safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy AT tasciottiannaelisa safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy AT schwarztino safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy AT fergusonmurdo safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy AT aroraashwanikumar safetyandimmunogenicityofthreedosesofnontypeablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccinewhenadministeredaccordingtotwodifferentschedulesaphase2randomisedobserverblindstudy |